Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the ...

Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the first treatment for C3G and primary IC-MPGN ...

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people.

Kanazawa University, in collaboration with Osaka University and the National Institutes for Quantum Science and Technology, ...

Inflammation has to fight pathogens fast—but it can't get out of control. Researchers at the German Cancer Research Center ...

A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...